Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: CNS Pharmaceuticals Inc. CNSP

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reaches Planned Enrollment Berubicin Study for the Treatment of GBM

Posted on January 18, 2024 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has completed enrollment in its global potentially pivotal study evaluating Berubicin. According to the announcement, … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces DSMB Recommendation to Continue Pivotal GBM Study without Modification

Posted on December 18, 2023 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced a recommendation from the independent Data Safety Monitoring Board (“DSMB”) regarding Berubicin, the … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Interim Analysis on Global Berubicin Trial Showing Promising Results

Posted on December 6, 2023 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. In September, the company announced that 200 out of 243 expected patients had been enrolled in its ongoing … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study at SNO Annual Gathering

Posted on November 22, 2023 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced the presentation of updated safety data from its ongoing potentially pivotal study … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin

Posted on November 16, 2023 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. The company today announced its confidence in sharing the results from an interim analysis on one of its … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2023 Financial Results, Update on Berubicin Study

Posted on November 15, 2023 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting on its financial results for third quarter, the period ended Sept. 30, … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment

Posted on October 20, 2023 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced rapid enrollment in its potentially pivotal study involving its flagship drug candidate, Berubicin, and is moving closer to reporting the results of its drive toward a new treatment for the effectively incurable brain cancer … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Ask the CEO Conference

Posted on October 19, 2023 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured at this month’s Virtual Investor Ask the CEO Conference. CNS Pharmaceuticals … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Innovative Glioblastoma Treatment ‘Could Offer Hope’

Posted on October 16, 2023 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in a recent article focused on glioblastoma, the most aggressive type of … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Rapid Pace of Enrollment in Potentially Pivotal Berubicin Study

Posted on October 11, 2023 by MissionIR

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting enrollment of 229 participants in its ongoing potentially pivotal study evaluating Berubicin for the … Continue reading →

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment